Granted Patent
B2
US 12,377,032 · App. 17/032,616 · Granted Aug 5, 2025
Compound for use in protecting skin
View Patent ↗
Loading inventors, assignments & file history…
Abstract
A method of protecting animal tissue particularly skin, from damage caused by radiation exposure, by contacting the tissue with a ketone ester, a method of protecting skin, reducing the deterioration of skin or maintaining or improving the properties of skin by applying topically to the skin a ketone body comprising (R)-3-hydroxybutyrate moieties is disclosed. A ketone body comprising (R)-3-hydroxybutyrate moieties, especially enantiomerically enriched R-1,3-hydroxybutyl-(R)-3-hydroxybutyrate, for such uses is also provided.
Claims (13)
1. A skin protection composition comprising (1) a (R)-3-hydroxybutyrate monoester of a dihydric or trihydric alcohol capable of being metabolized in skin cells and (2) an excipient for topical application.
2. The skin protection composition of claim 1 wherein the excipient comprises a cosmetically acceptable carrier.
3. The skin protection composition of claim 1 comprising at least 1% by weight of the (R)-3-hydroxybutyrate monoester in the composition.
4. The skin protection composition of claim 1 wherein the excipient comprises polyethylene glycol.
5. The skin protection composition of claim 1 comprising a medium-chain triglyceride or a fatty acid with a chain length of 5 to 12 carbon atoms.
6. The skin protection composition of claim 1 in the form of a gel, cream, lotion, mousse or aerosol.
7. The skin protection composition of claim 1 , wherein the excipient for topical application aids spreading across the skin or absorption into the skin of the (R)-3-hydroxybutyrate monoester.
8. The skin protection composition of claim 1 further comprising at least one of an oligomer of hydroxybutyrate, triolide, acetoacetate, a salt of (R)-3-hydroxybutryrate and esters thereof, an acetoacetyl oligomer, or any precursor of beta hydroxybutyrate that is capable of being metabolized in skin cells.
9. The skin protection composition of claim 1 wherein the (R)-3-hydroxybutyrate monoester comprises 1,3-hydroxybutyl-(R)-3-hydroxybutyrate.
10. The skin protection composition of claim 1 wherein the (R)-3-hydroxybutyrate monoester comprises enantiomerically enriched (R)-1,3-hydroxybutyl-(R)-3-hydroxybutyrate.
11. A method of protecting skin, reducing the deterioration of skin, or maintaining or improving properties of skin in a subject in need thereof, said method comprising applying topically to the skin of the subject the skin protection composition of claim 1 .
12. The method of claim 11 further providing an anti-ageing effect in the skin of the subject.
13. The method of claim 11 , wherein the deterioration of skin that is reduced is due to ageing or due to the harmful effects of radiation.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 28, 2023
From: CLARKE, KIERAN
To: TDELTAS LIMITED
Reel/Frame 063133/0877 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 28, 2023
From: VEECH, RICHARD LEWIS
To: GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF OF HEALTH AND HUMAN SERVICES
Reel/Frame 063135/0529 →
Priority Claims (1)
GB 1304467
· Mar 12, 2013
· national
Continuity (2)
Continuation
14774856
References Cited (256)
US 3984566A
· Van Scott et al.
· 1976
[cited by applicant]
US 4380549A
· Van Scott
· 1983
[cited by examiner]
US 5112865A
· Nichels et al.
· 1992
[cited by applicant]
US 5281691A
· Hubbs et al.
· 1994
[cited by applicant]
US 5468507A
· Czap
· 1995
[cited by applicant]
US 5654266A
· Chen et al.
· 1997
[cited by applicant]
US 5665831A
· Neuenschwander et al.
· 1997
[cited by applicant]
US 5693850A
· Birkhahn et al.
· 1997
[cited by applicant]
US 6126953A
· Costa et al.
· 2000
[cited by applicant]
US 6136862A
· Hiraide et al.
· 2000
[cited by applicant]
US 6207856B1
· Veech
· 2001
[cited by applicant]
US 6268167B1
· Wild et al.
· 2001
[cited by applicant]
US 6316038B1
· Veech
· 2001
[cited by applicant]
US 6323237B1
· Veech
· 2001
[cited by applicant]
US 6380244B2
· Martin et al.
· 2002
[cited by applicant]
US 6544960B1
· Eldred et al.
· 2003
[cited by applicant]
US 6939570B1
· Snow et al.
· 2005
[cited by applicant]
US 7351736B2
· Veech
· 2008
[cited by applicant]
US 7947736B2
· Gross
· 2011
[cited by applicant]
US 8101653B2
· Veech
· 2012
[cited by applicant]
US 8642654B2
· Clarke et al.
· 2014
[cited by applicant]
US 9034613B2
· Robertson et al.
· 2015
[cited by applicant]
US 9211275B2
· Clarke et al.
· 2015
[cited by applicant]
US 9579302B2
· Veech et al.
· 2017
[cited by applicant]
US 20010014696A1
· Veech et al.
· 2001
[cited by applicant]
US 20010041741A1
· Sole et al.
· 2001
[cited by applicant]
US 20010047008A1
· Baraldi
· 2001
[cited by applicant]
US 20020006959A1
· Henderson
· 2002
[cited by applicant]
US 20020013339A1
· Martin et al.
· 2002
[cited by applicant]
US 20020035231A1
· Whitehouse et al.
· 2002
[cited by applicant]
US 20030022937A1
· Veech et al.
· 2003
[cited by applicant]
US 20040063661A1
· Linnane
· 2004
[cited by applicant]
US 20050129783A1
· McCleary et al.
· 2005
[cited by applicant]
US 20050165318A1
· Brodnick et al.
· 2005
[cited by applicant]
US 20050181275A1
· Jang
· 2005
[cited by applicant]
US 20060078596A1
· Clarke et al.
· 2006
[cited by applicant]
US 20060280721A1
· Veech et al.
· 2006
[cited by applicant]
US 20070179197A1
· Henderson et al.
· 2007
[cited by applicant]
US 20090253781A1
· Veech
· 2009
[cited by applicant]
US 20120071548A1
· Veech
· 2012
[cited by applicant]
US 20120213835A1
· Neas et al.
· 2012
[cited by applicant]
US 20150065571A1
· Clarke et al.
· 2015
[cited by applicant]
US 20150164855A1
· Clarke et al.
· 2015
[cited by applicant]
US 20190014798A1
· Clarke et al.
· 2019
[cited by applicant]
CA 1330307C
· 1994
[cited by applicant]
CA 2173270A
· 1996
[cited by applicant]
CN 1483355A
· 2002
[cited by applicant]
CN 1552315A
· 2004
[cited by applicant]
DE 20205184U
· 2002
[cited by applicant]
EP 0266217A2
· 1988
[cited by applicant]
EP 0537113A1
· 1993
[cited by applicant]
EP 0552896A1
· 1993
[cited by applicant]
EP 0721740A1
· 1996
[cited by applicant]
EP 1568780A1
· 2005
[cited by applicant]
EP 1809235B1
· 2007
[cited by applicant]
EP 2875812A1
· 2015
[cited by applicant]
GB 1524611A
· 1978
[cited by applicant]
GB 03126034
· 2003
[cited by applicant]
GB 03137601
· 2003
[cited by applicant]
GB 2511941A
· 2014
[cited by applicant]
JP S54138126A
· 1979
[cited by applicant]
JP S5747446A
· 1982
[cited by applicant]
JP S63112998A
· 1988
[cited by applicant]
JP H01095730A
· 1989
[cited by applicant]
JP H01160917A
· 1989
[cited by applicant]
JP H03083950A
· 1991
[cited by applicant]
JP H04112825A
· 1992
[cited by applicant]
JP H06256157A
· 1994
[cited by applicant]
JP H07076513A
· 1995
[cited by applicant]
JP H08191664A
· 1996
[cited by applicant]
JP H10175855A
· 1998
[cited by applicant]
JP H10265378A
· 1998
[cited by applicant]
JP H10313819A
· 1998
[cited by applicant]
JP 2001515510A
· 2001
[cited by applicant]
JP 2005247821A
· 2005
[cited by applicant]
JP 2008513017A
· 2008
[cited by applicant]
JP 2008127369A
· 2008
[cited by applicant]
JP 2008263825A
· 2008
[cited by applicant]
JP 2009532496A
· 2009
[cited by applicant]
JP 2012500264A
· 2012
[cited by applicant]
JP 2016512207A
· 2016
[cited by applicant]
SU 507322A
· 1976
[cited by applicant]
WO WO1987003806A1
· 1987
[cited by applicant]
WO WO1991004735A1
· 1991
[cited by applicant]
WO WO1995009144A1
· 1995
[cited by applicant]
WO WO1998041200A1
· 1998
[cited by applicant]
WO WO1998041201A1
· 1998
[cited by applicant]
WO WO1999024451A2
· 1999
[cited by applicant]
WO WO2000004895A1
· 2000
[cited by applicant]
WO WO2000015216A1
· 2000
[cited by applicant]
WO WO2001013877A1
· 2001
[cited by applicant]
WO WO2001051645A1
· 2001
[cited by applicant]
WO WO2002006368A2
· 2002
[cited by applicant]
WO WO2003012417A2
· 2003
[cited by applicant]
WO WO2003056319A2
· 2003
[cited by applicant]
WO WO2003097860A1
· 2003
[cited by applicant]
WO WO2004105742A1
· 2004
[cited by applicant]
WO WO2004108740A1
· 2004
[cited by applicant]
WO WO2006020137A2
· 2006
[cited by applicant]
WO WO2006031941A2
· 2006
[cited by applicant]
WO WO2006061624A1
· 2006
[cited by applicant]
WO WO2006070337A2
· 2006
[cited by applicant]
WO WO2007001883A2
· 2007
[cited by applicant]
WO WO2007063037A2
· 2007
[cited by applicant]
WO WO2007115282A2
· 2007
[cited by applicant]
WO WO2007115934A1
· 2007
[cited by applicant]
WO WO2008074473A2
· 2008
[cited by applicant]
WO WO2008110034A1
· 2008
[cited by examiner]
WO WO2008119032A1
· 2008
[cited by applicant]
WO WO2008140828A1
· 2008
[cited by applicant]
WO WO2009023357A2
· 2009
[cited by applicant]
WO WO2009045481A1
· 2009
[cited by applicant]
WO WO2009089144A1
· 2009
[cited by applicant]
WO WO2010021766A1
· 2010
[cited by applicant]
WO WO2010120300A1
· 2010
[cited by applicant]
WO WO2011101171A1
· 2011
[cited by applicant]
WO WO2011121540A1
· 2011
[cited by applicant]
WO WO2012113415A1
· 2012
[cited by applicant]
WO WO2013150153A1
· 2013
[cited by applicant]
WO WO2014071389A1
· 2014
[cited by applicant]
WO WO2014139599A1
· 2014
[cited by applicant]
WO WO2014153416A1
· 2014
[cited by applicant]
“Drug Therapy of Dyslipidemia” in Goodman & Gilman's the Pharmacological Basis of Therapeutics, 11th Ed., McGraw-Hill (New York), pp. 948-953 (2006).
[cited by applicant]
Abdelwahab et al., “The Ketogenic Diet is an Effective Adjuvant to Radiation Therapy for the Treatment of Malignant Glioma”, PLOS One 7(5):E36197, pp. 1-7 (2012).
[cited by applicant]
Baron et al., “Mechanism of insulin resistance in insulin-dependent diabetes mellitus: a major role for reduced skeletal muscle blood flow”,
[cited by applicant]
Boehm et al., “Increased uncoupling proteins and decreased efficiency in the palmitate-perfused hyperthyroid rat heart”,
[cited by applicant]
Boyarinov et al., “Effect of Sodium hydroxybutyrate on myocardial high-energy phosphates, function, and ultrastructure after blood loss”,
[cited by applicant]
Buteau, “Obviousness of Enantiomers over Prior Art Racemates,”
[cited by applicant]
Casey et al., In; Advanced Practical Organic Chemistry. Blackie. Glasgow and London, U.K. pp. 158-160 (1990).
[cited by applicant]
Chatham et al., “Preferential inhibition of lactate oxidation relative to glucose oxidation in the rat heart following diabetes”,
[cited by applicant]
Chatham et al., “Cardiac carbohydrate metabolism in Zucker diabetic fatty rats”,
[cited by applicant]
Chen et al., “Beta-hydroxybutyrate reduces alcoholic steatohepatits (ASH) via activation of the GPR 109A Receptor”,
[cited by applicant]
Chen et al., “β-hydroxybutyrate protects from alcoholic hepatitis via a GPR109a-C/EBPβ dependent pathway”, AASLD Liver Learning. Abstract No. 1629. Accessible on the Internet at URL: http://liverlearning.aasld.org/aasld…
[cited by applicant]
Clark et al., “Dilated Cardiomyopathy and Acute Liver Injury Associated with Combined Use of Ephedra, yHydroxybutyrate, and Anabolic Steroids”,
[cited by applicant]
Clarke et al., “Oral 28-day and developmental toxicity studies of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate”,
[cited by applicant]
Cole et al., “A high fat diet increases mitochondrial fatty acid oxidation and uncoupling to decrease efficiency in rat heart”,
[cited by applicant]
Cox et al., “Acute nutritional ketosis: implications for exercise performance and metabolism”,
[cited by applicant]
Davey et al., “Radioprotection of rat subependymal plate with 4-0H sodium butyrate”,
[cited by applicant]
Demir et al., “Serum HbA1c levels and exercise capacity in diabetic patients”,
[cited by applicant]
Desrochers et al., “Metabolism of R and S-1 ,3-butanediol in perfused livers from meal-fed and starved rats”,
[cited by applicant]
Desrochers et al., “Metabolism of (R,S)-1 ,3-butanediol acetoacetate esters, potential parenteral and enteral nutrients in conscious pigs”,
[cited by applicant]
Desrochers et al., “R, S-1, 3-butanediol acetoacetate esters, potential alternates to lipid emulsions for total parenteral nutrition”,
[cited by applicant]
Eagles et al., “The effects of combined treatment with β1-selective receptor antagonists and lipid-lowering drugs on fat metabolism and measures of fatigue during moderate intensity exercise: a placebo-controlled study …
[cited by applicant]
Edegger et al., “Regia- and Stereoselective Reduction of Diketones and Oxidation of Dials by Biocatalytic Hydrogen Transfer”,
[cited by applicant]
Estacio et al., “The association between diabetic complications and exercise capacity in NIDDM patients”,
[cited by applicant]
Examination Report corresponding to Great Britain Patent Application No. 1404400.2, dated Aug. 18, 2014.
[cited by applicant]
Farmer et al., “Radioprotective Thiazolidines from beta-keto esters”,
[cited by applicant]
Felig et al., “Amino acid metabolism in exercising man”,
[cited by applicant]
Frayn, In; Metabolic Regulation: A Human Perspective, 2nd Ed. Blackwell Science, pp. 94-96 (2003).
[cited by applicant]
Gangemi, “Enhancing Athletic Performance by Predicting Fatigue and Preventing Muscle Failure”, Accessible on the Internet at URL: http://www.drgangemi.com/wp-content/uploads/2011/01/GANGEMI-PREDICTING-FATIGUE-AND-MUSCLE…
[cited by applicant]
Goldbort et al., “Butanediols: Selection, open field activity, and NAD reduction by liver extracts in inbred mouse strains”,
[cited by applicant]
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/US2009/030095, issued Jul. 6, 2010.
[cited by applicant]
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/US2009/040773, issued Oct. 18, 2011.
[cited by applicant]
International Preliminary Report on Patentability corresponding to International Patent Application No. PCT/EP2013/069189, issued Sep. 15, 2015.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/GB2004/002286, mailed Oct. 11, 2004.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2011/000833, mailed Jun. 22, 2011.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2013/057250, mailed Jun. 11, 2013.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2013/069189, mailed Aug. 12, 2014.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2014/055158, mailed Jun. 25, 2014.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/EP2014/067027, mailed Oct. 30, 2014.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2004/018016, mailed Apr. 15, 2005.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2009/030095, issued Feb. 23, 2009.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2009/040766, mailed Aug. 6, 2009.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2009/040773, mailed Feb. 22, 2010.
[cited by applicant]
International Search Report with Written Opinion corresponding to International Patent Application No. PCT/US2013/068545, mailed Jan. 20, 2014.
[cited by applicant]
Iozzo et al., “Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with Type II diabetes”,
[cited by applicant]
Kalaitzakis et al., “Highly Stereoselective Reductions of α-Alkyl-1,3-diketones and α-Alkyl-β-keto Esters Catalyzed by Isolated NADPH-Dependent Ketoreductases”,
[cited by applicant]
Kashiwaya et al., “A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease”,
[cited by applicant]
Kemper et al., “An Ester of β-Hydroxybutyrate Regulates Cholesterol Biosynthesis in Rats and a Cholesterol Biomarker in Human”,
[cited by applicant]
Knowler et al., “Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention of Metformin”,
[cited by applicant]
Kohut et al., “Effects of decreased free fatty acids on fatigue during exercise with carbohydrate feedings”,
[cited by applicant]
Komiyama et al., “Near-infrared spectroscopy grades the severity of intermittent claudication in diabetes more accurately than ankle pressure measurement”,
[cited by applicant]
Komiyama et al., “Effects of a 4-week 70% high carbohydrate / 15% low fat diet on glucose tolerance and on lipid profiles”,
[cited by applicant]
Kulinskii et al., “The radioprotective effect of GABA-tropic substances, gamma-hydroxybutyrate and piracetam”,
[cited by applicant]
Kwiterovich et al., “Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children”,
[cited by applicant]
Laffel, “Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes”,
[cited by applicant]
Lanni et al., “De Novo Expression of Uncoupling Protein 3 is Associated to Enhanced Mitochondrial Thioesterase-1 Expression and Fatty Acid Metabolism in Liver of Fenofibrate-treated Rats”,
[cited by applicant]
Larios et al., “Synthesis of flavor and fragrance esters using Candida antarctica lipase”,
[cited by applicant]
Leckey et al., “Ketone Diester Ingestion Impairs Time-Trial Performance in Professional Cyclists”,
[cited by applicant]
Ley, “Masking Bitter Taste by Molecules”,
[cited by applicant]
Libby et al., “Diabetic macrovascular disease. The glucose paradox?”
[cited by applicant]
Lodi et al., “Reduced cytosolic acidification during exercise suggests defective glycolytic activity in skeletal muscle of patients with Becker muscular dystrophy. An in vivo 31P magnetic resonance spectroscopy study”,
[cited by applicant]
Lunde et al., “Skeletal muscle fatigue in normal subjects and heart failure patients. Is there a common mechanism?”
[cited by applicant]
Madsen et al., “Near-infrared oximetry of the brain”,
[cited by applicant]
Mahler et al., “Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment”,
[cited by applicant]
Meyer et al., “Myocardial blood flow and glucose metabolism in diabetes mellitus”,
[cited by applicant]
Mori et al., “Synthesis of the Propionates of (2R, 8R)- and (2S, 8R)-8-methyl-2-decanol, the pheromone of the Western corn rootworm, employing chiral compounds of microbial origin as starting material”,
[cited by applicant]
Mori et al., “New synthesis of both enantiomers of grandisol, the boll weevil pheromon”,
[cited by applicant]
Murray et al., “Uncoupling Proteins in Human Heart”,
[cited by applicant]
Murray et al., “Plasma Free Fatty Acids and Peroxisome Proliferator-Activated Receptor a in the Control of Myocardial Uncoupling Protein Levels”,
[cited by applicant]
Nair et al., “Effect of beta-hydroxybutyrate on whole-body leucine kinetics and fractional mixed skeletal muscle protein synthesis in humans”,
[cited by applicant]
Neubauer et al., “Myocardial phosphocreatine-to-ATP Ratio is a predictor of mortality in patients with dilated cardiomyopathy”,
[cited by applicant]
Newsholme et al., In; Biochemistry for the Medical Sciences. John Wiley & Sons. Chichester, U.K., pp. 324-331 (1986).
[cited by applicant]
Ojeda et al., “[Radiation response of mitochondria in dependence on their metabolic status (author's transl)]”,
[cited by applicant]
O'Neill et al., “A simple enantioselective synthesis of γ-valerolactone”,
[cited by applicant]
Ostrovskaya et al., “Effect of prolonged administration of sodium hydroxybutyrate on the working capacity and muscle tissue in rats”,
[cited by applicant]
Paolisso et al., “Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease”,
[cited by applicant]
Perez-Jimenez et al., “A Mediterranean and a high-carbohydrate diet improve glucose metabolism in healthy young persons”,
[cited by applicant]
Puchowicz et al., “Dog model of therapeutic ketosis induced by oral administration of R,S-1,3-butanediol diacetoacetate”,
[cited by applicant]
Richieri et al., “Unbound free fatty acid levels in human serum”,
[cited by applicant]
Rodrigues et al., “Metabolic disturbances in diabetic cardiomyopathy”,
[cited by applicant]
Rossi et al., “Suppression of Feed Intake after Parenteral Administration of D-ββ-Hydroxybutyrate in Pygmy Goats”,
[cited by applicant]
Salehizadeh et al., “Production of polyhydroxyalkanoates by mixed culture: recent trends and biotechnological importance”,
[cited by applicant]
Sato et al., “Insulin, ketone bodies, and mitochondria! energy transduction”,
[cited by applicant]
Scheuermann-Freestone et al., “Abnormal cardiac and skeletal muscle energy metabolism in patients with type 2 diabetes”,
[cited by applicant]
Search Report corresponding to Great Britain Patent Application No. 1002983.3, dated Jun. 10, 2010.
[cited by applicant]
Search Report corresponding to Great Britain Patent Application No. 1304467.2, dated Aug. 23, 2013.
[cited by applicant]
Search Report corresponding to Great Britain Patent Application No. 1314127.0, dated Jan. 31, 2014.
[cited by applicant]
Search and Examination Report corresponding to Great Britain Patent Application No. 1404400.2, dated Mar. 26, 2014.
[cited by applicant]
Search and Examination Report corresponding to Great Britain Patent Application No. 1414016.4, dated Aug. 29, 2014.
[cited by applicant]
Search and Examination Report corresponding to Great Britain Patent Application No. 1404577.7, dated Oct. 23, 2014.
[cited by applicant]
Seebach et al., “Direct Degradation of the Biopolymer Poly[(R)-3-Hydroxybutyric Acid] to (R)-3-Hydroxybutanoic Acid and its Methyl Ester,”
[cited by applicant]
Shaw et al., “Influence of beta-hydroxybutyrate infusion on glucose and free fatty acid metabolism in dogs”,
[cited by applicant]
Sherwin et al., “Effect of ketone infusions on amino acid and nitrogen metabolism in man”,
[cited by applicant]
Sidell et al., “Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart”,
[cited by applicant]
Silva et al., “Poly-3-hydroxybutyrate (P3HB) production by bacteria from xylose, glucose and sugarcane bagasse hydrolysate”,
[cited by applicant]
Simons et al., “Long Term Treatment with Slow Release Oxprenolol Alone, or in Combination with other Drugs: Effects on Blood Pressure, Lipoproteins and Exercise Performance”,
[cited by applicant]
Smith et al., “Initial effect of injury on ketone bodies and other blood metabolites”,
[cited by applicant]
Smith et al., “Magnetic Resonance Spectroscopy in Medicine: Clinical Impact”,
[cited by applicant]
Stanley et al., “Regulation of energy substrate metabolism in the diabetic heart”,
[cited by applicant]
Supplementary European Search Report and Written Opinion corresponding to European Patent Application No. 09701051.6, dated Jan. 19, 2011.
[cited by applicant]
Suzuki et al., “Acetylputrescine deacetylase from Micrococcus luteus K-11”,
[cited by applicant]
Taegtmeyer et al., “Adaptation and maladaptation of the heart in diabetes: Part I. General concepts”,
[cited by applicant]
Tinnikov et al., “Colorimetric micro-determination of free fatty acids in plasma using microplate readers”,
[cited by applicant]
Tlili et al., “The caper (
[cited by applicant]
Tobin et al., “Effect of 1 ,3-Butanediol and Propionic Acid on Blood Ketones, Lipids and Metal Ions in Rats”,
[cited by applicant]
Toubro et al., “Twenty-four-hour respiratory quotient: the role of diet and familial resemblance”,
[cited by applicant]
Tunaru et al., “PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect”,
[cited by applicant]
Turner et al., “Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)”,
[cited by applicant]
Westerblad et al., “Recent advances in the understanding of skeletal muscle fatigue”,
[cited by applicant]
Wilson, “Evaluation of Skeletal Muscle Fatigue in Patients with Heart Failure”,
[cited by applicant]
Wu et al., “Ketone bodies inhibit leucine degradation in chick skeletal muscle”,
[cited by applicant]
Zange et al., “Creatine Supplementation Results in Elevated Phosphocreatine/Adenosine Triphosphate (ATP) Ratios in the Calf Muscle of Athletes but Not in Patients with Myopathies”,
[cited by applicant]
Zhu et al., “A recombinant ketoreductase tool-box. Assessing the substrate selectivity and stereoselectivity toward the reduction of β-ketoesters”,
[cited by applicant]